Mazdutide Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Mazdutide evidence and protocol review

Metabolic Research peptide Injection solutionLyophilized research material verified

Also known as: IBI362, LY3305677

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

3 mg, 4.5 mg, 6 mg published weekly target doses, 5 mg, 10 mg, 20 mg RUO vials; RUO vials are not approved U.S. presentations

Calculator

Preset available

Storage

No US FDA label as of 2026. Use source COA / approved-market labeling and verify independently before recording.

Solubility

Aqueous injectable solution; acylated peptide for SC delivery

Catalog Description

Mazdutide is a dual glucagon (GCG)/GLP-1 receptor agonist. In a head-to-head Phase 3 trial reported in Chinese adults with type 2 diabetes, mazdutide produced superior results to semaglutide at week 32: HbA1c reduction of -2.03% vs. -1.84%, and mean weight reduction of 10.29% vs. 6.00%. Results were published in Nature. Innovent describes mazdutide as the first approved GCG/GLP-1 dual receptor agonist for glycemic control and weight management (China approval); it is not FDA-approved in the United States as of 2026.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Supports weekly dosing regimen in published trials (specific half-life not yet corroborated by two independent sources)

Onset

Progressive over 32-week trial period

Administration Routes (Research)

Reported Research Effects

Superior HbA1c reduction vs. semaglutide in head-to-head Chinese Phase 3 trial
Superior weight reduction vs. semaglutide in same trial
Dual glucagon/GLP-1 receptor activation

Reported Research Side Effects

Human safety, pharmacokinetics, and interaction data are incomplete

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

3 mg target arm: weeks 1-4 1.5 mg, weeks 5-24 3 mg [SC; 24-week Phase 2 regimen; Weekly]Source: NCT04904913 publication
4.5 mg target arm: weeks 1-4 1.5 mg, weeks 5-8 3 mg, weeks 9-24 4.5 mg [SC; 24-week Phase 2 regimen; Weekly]Source: NCT04904913 publication
6 mg target arm: weeks 1-4 2 mg, weeks 5-8 4 mg, weeks 9-24 6 mg [SC; 24-week Phase 2 regimen; Weekly]Source: NCT04904913 publication

Research Notes

Published escalation tables are investigational study regimens, not a U.S. prescribing schedule. Mazdutide received approvals in China in 2025 but is not FDA-approved in the United States; RUO vial sizes are market observations, not approved strengths.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Mazdutide Phase 2 randomized trial with explicit escalation schedules — PubMed Central (NIH)
https://pmc.ncbi.nlm.nih.gov/articles/PMC10719339/

Mazdutide GLORY-1 Phase 3 trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/40421736/

Mazdutide first-approval review — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/41028652/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.